Comparative Pharmacology
Head-to-head clinical analysis: MAXOLON versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MAXOLON versus PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE.
MAXOLON vs PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Metoclopramide, the active ingredient in MAXOLON, is a dopamine D2 receptor antagonist and also enhances the response to acetylcholine at muscarinic receptors in the gastrointestinal tract, leading to increased gastric motility and accelerated gastric emptying. It also has antiemetic effects by blocking dopamine receptors in the chemoreceptor trigger zone (CTZ).
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
10 mg orally, intramuscularly, or intravenously three to four times daily. Maximum daily dose: 30 mg or 0.5 mg/kg.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
None Documented
None Documented
5-6 hours in adults with normal renal function; prolonged to 15-20 hours in severe renal impairment (CrCl <10 mL/min).
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Renal: 85-95% as unchanged drug and metabolites; biliary/fecal: <5%.
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Category C
Category A/B
Antiemetic
Antihistamine / Antiemetic